Streetbeat News

Products Services

KSCP

Knightscope's agreement with an American hospitality company has been renewed for the third year. The company will deploy K5 Autonomous Security Robots and Risk & Threat Exposure Analyst Services in Houston and Atlanta.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:41 pm

The focus on High Bandwidth Memory (HBM) production by Samsung Electronics, SK hynix, and Micron is causing a significant increase in the prices of legacy DRAM products. Market research firms predict that DDR3 prices could rise by 50-100% in the second half of the year due to reduced production capacity. DDR4 prices are also increasing across various categories. This trend is expected to continue, leading to a supply-demand imbalance and potentially boosting the financial performance of chip manufacturers.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:40 pm

ALLG

AVTE

MBIO

OVID

SCNI

SCPX

US stocks showed mixed performance with the Dow Jones falling over 100 points, while the NASDAQ saw a slight rise. Key movers included Mustang Bio, Allego N.V., and Scinai Immunotherapeutics, which saw significant gains, while Aerovate Therapeutics, Scorpius Holdings, and Ovid Therapeutics experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 1:40 pm

BTCUSD

ETHUSD

Prominent crypto analyst Ted highlights key economic indicators and central bank actions that could impact Bitcoin's price in the upcoming week. Despite positive inflation data, the Federal Reserve's cautious messaging and revised rate cut expectations could influence market sentiment. Bitcoin must maintain its $66,000 support level to avoid significant sell-offs.

Portfolio Pulse from Khyathi Dalal

June 17, 2024 | 1:39 pm

AMC

AMC Theatres reported its highest attendance and admissions revenue of 2024 during the June 13-16 weekend, driven by the releases of 'Inside Out 2' and 'Bad Boys: Ride Or Die'. The company saw over 1 million moviegoers each day and experienced double-digit international growth.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:30 pm

BTI

CNBS

CURLF

GTBIF

OGI

TCNNF

Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF (NYSE:CNBS), discusses the growth potential in the cannabis sector, emphasizing the importance of strategic partnerships, operational efficiencies, and the burgeoning U.S. hemp cannabinoid market. He highlights companies like Curaleaf, Green Thumb Industries, and Trulieve for their strong market positions and governance. Seymour also notes British Tobacco's investment in Organigram as a strategic move to expand international market reach.

Portfolio Pulse from Nicolás Jose Rodriguez

June 17, 2024 | 1:26 pm

SLYV

SPY

A Reddit discussion highlights the need to adjust market cap definitions for inflation, as small-cap value stocks lag 20% behind the S&P 500. The SPDR S&P 600 Small Cap Value ETF (SLYV) is down 8.31% YTD, while the SPDR S&P 500 ETF (SPY) has gained 14.19%. Adjusting market cap thresholds could provide a more accurate representation of company sizes and aid in better investment decisions.

Portfolio Pulse from Surbhi Jain

June 17, 2024 | 1:22 pm

FBIO

MBIO

Mustang Bio Inc (NASDAQ:MBIO) shares surged over 190% on Monday following the announcement of positive Phase 1/2 trial results for their CAR T-cell therapy, MB-106, targeting Waldenstrom macroglobulinemia. The trial showed a 90% response rate with favorable safety outcomes. The company, founded by Fortress Biotech Inc (NASDAQ:FBIO), presented these results at the European Hematology Association 2024 Hybrid Congress.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 1:21 pm

GOOGL

STGW

Stagwell announced the integration of Google Cloud and Gemini AI models into four of its popular digital marketing apps. The new AI-powered features were unveiled at the Cannes event, leveraging Google Cloud's infrastructure and AI services.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:15 pm

MRNS

Marinus Pharmaceuticals announced mixed results from its Phase 3 RAISE trial for IV ganaxolone in treating refractory status epilepticus (RSE). While the drug showed significant efficacy in stopping status epilepticus within 30 minutes, it failed to achieve statistical significance in preventing progression to IV anesthesia. The company plans to continue analyzing the data and engage with the FDA for further steps.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 1:14 pm